A detailed history of Morgan Stanley transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 836,210 shares of ITCI stock, worth $106 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
836,210
Previous 1,029,869 18.8%
Holding current value
$106 Million
Previous $70.5 Million 13.32%
% of portfolio
0.0%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $13.2 Million - $15.7 Million
-193,659 Reduced 18.8%
836,210 $61.1 Million
Q2 2024

Oct 17, 2024

BUY
$64.76 - $79.84 $5.83 Million - $7.19 Million
90,072 Added 9.58%
1,029,869 $70.5 Million
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $5.83 Million - $7.19 Million
90,072 Added 9.58%
1,029,869 $70.5 Million
Q1 2024

Oct 17, 2024

SELL
$64.37 - $75.65 $5.8 Million - $6.81 Million
-90,072 Reduced 8.75%
939,797 $65 Million
Q1 2024

Aug 16, 2024

SELL
$64.37 - $75.65 $19.5 Million - $22.9 Million
-302,223 Reduced 24.33%
939,797 $65 Million
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $19.5 Million - $22.9 Million
-302,223 Reduced 24.33%
939,797 $65 Million
Q4 2023

Aug 16, 2024

BUY
$46.37 - $73.65 $9.84 Million - $15.6 Million
212,151 Added 20.6%
1,242,020 $89 Million
Q4 2023

Feb 13, 2024

BUY
$46.37 - $73.65 $14.2 Million - $22.6 Million
306,433 Added 32.75%
1,242,020 $89 Million
Q3 2023

Nov 15, 2023

SELL
$52.09 - $64.1 $4.78 Million - $5.89 Million
-91,838 Reduced 8.94%
935,587 $48.7 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $17.2 Million - $20.8 Million
313,800 Added 43.97%
1,027,425 $65.1 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $10.8 Million - $14.1 Million
-246,593 Reduced 25.68%
713,625 $38.6 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $3.96 Million - $4.89 Million
89,758 Added 10.31%
960,218 $50.8 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $3.97 Million - $5.57 Million
92,923 Added 11.95%
870,460 $40.5 Million
Q2 2022

Oct 27, 2022

BUY
$43.0 - $65.64 $5.31 Million - $8.11 Million
123,553 Added 18.89%
777,537 $44.4 Million
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $5.31 Million - $8.11 Million
123,553 Added 18.89%
777,537 $44.4 Million
Q1 2022

Oct 27, 2022

SELL
$38.74 - $62.09 $4.79 Million - $7.67 Million
-123,553 Reduced 15.89%
653,984 $40 Million
Q1 2022

May 13, 2022

SELL
$38.74 - $62.09 $1.59 Million - $2.54 Million
-40,914 Reduced 5.89%
653,984 $40 Million
Q4 2021

Feb 14, 2022

SELL
$35.2 - $53.42 $1.52 Million - $2.3 Million
-43,122 Reduced 5.84%
694,898 $36.4 Million
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $21.2 Million - $31.4 Million
738,020 New
738,020 $27.5 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $12B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.